Anti-Inflammatory Effects of M-MSCs in DNCB-Induced Atopic Dermatitis Mice

Atopic dermatitis (AD) is an inflammatory skin disease caused by an imbalance between Th1 and Th2 cells. AD patients suffer from pruritus, excessive dryness, red or inflamed skin, and complications such as sleep disturbances and depression. Although there are currently many AD treatments available t...

Full description

Saved in:
Bibliographic Details
Published in:Biomedicines 2020-10, Vol.8 (10), p.439
Main Authors: Ryu, Bokyeong, Baek, Jieun, Kim, Hana, Lee, Ji-Heon, Kim, Jin, Jeong, Young-Hoon, Lee, Seul-Gi, Kang, Kyu-Ree, Oh, Min-Seok, Kim, Eun-Young, Kim, C-Yoon, Chung, Hyung
Format: Article
Language:English
Subjects:
Amino acids
Antibodies
Atopic dermatitis
atopic dermatitis (AD)
Bone marrow
Cytokines
Dermatitis
Embryo cells
embryonic stem cell (ESC)
Gene expression
Helper cells
Histamine
Humidity
Immune response
Immunoglobulin E
Immunoregulation
inflammation
Lymphocytes T
mesenchymal stem cell (MSC)
Mesenchyme
Proteins
Pruritus
Secretions
Skin
Skin diseases
Software
Stem cell transplantation
Stem cells
treatment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Atopic dermatitis (AD) is an inflammatory skin disease caused by an imbalance between Th1 and Th2 cells. AD patients suffer from pruritus, excessive dryness, red or inflamed skin, and complications such as sleep disturbances and depression. Although there are currently many AD treatments available there are insufficient data on their long-term stability and comparative effects. Moreover, they have limitations due to various side effects. Multipotent mesenchymal stem cells (M-MSCs) might have potential for next-generation AD therapies. MSCs are capable of immune function regulation and local inflammatory response inhibition. M-MSCs, derived from human embryonic stem cells (hESC), additionally have a stable supply. In L507 antibody array, M-MSCs generally showed similar tendencies to bone marrow-derived mesenchymal stem cells (BM-MSCs), although the immunoregulatory function of M-MSCs seemed to be superior to BM-MSCs. Based on the characteristics of M-MSCs on immunoregulatory functions, we tested a M-MSC conditioned media concentrate (MCMC) in mice with AD lesions on their dorsal skin. MCMC significantly decreased RNA expression levels of inflammatory cytokines in the mouse dorsal skin. It also suppressed serum IgE levels. In addition, significant histopathologic alleviation was identified. In conclusion, secretions of M-MSCs have the potential to effectively improve AD-related inflammatory lesions. M-MSCs showed potential for use in next-generation AD treatment.
ISSN:2227-9059
2227-9059
DOI:10.3390/biomedicines8100439